乐
乐观
乐观 · 25%EXOZ
$12.90
情景价格
$4.400
+0.311 (+7.06%)收盘时
Loading chart…
- 最高
- 4.585
- 开盘
- 4.190
- 成交量加权均价
- 4.37
- 成交量
- 10.79K
- 市值
- —
- 最低
- 4.110
- 成交额
- 47.09K
- 企业价值/息税折旧摊销前利润（TTM）
- 0.00
eXoZymes Inc, formerly Invizyne Technologies, Inc., is an artificial intelligence (AI) engineered enzyme that can transform sustainable feedstock into essential chemicals, medicines, and biofuels. The Company has developed a platform that offers the tools and insight to control and optimize nature’s own biological processes, enabling their partners to replace traditional chemical production methods with a new sustainable and non-polluting alternative. The Exozymes are advanced enzymes engineered using AI to thrive in a bioreactor outside of living cells.
AI 分析 of eXoZymes Inc (EXOZ)
买入Exozymes Inc. is a good buy right now due to its recent positive momentum and funding support. The current price is $4.52, and the stock has seen a 5-day change of +20.53%, indicating strong short-term performance. Additionally, the company secured a $2.02 million NIH grant, which enhances its financial backing and growth potential. However, the main risk is the negative earnings trend, with a projected EPS of -0.33 for the last quarter, reflecting ongoing losses.
估值指标
eXoZymes Inc（EXOZ）当前预期市盈率为 0.00，5 年平均预期市盈率为 0.00。
Alphio AI 对 EXOZ 的价格情景
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。
事件时间线
资讯
8.506-24seekingalphaeXoZymes Secures $2.02M NIH Grant for Cannabinoid Research
- 8.506-08seekingalpha
eXoZymes Prices Public Offering to Raise $5.33 Million
9.504-07Yahoo FinanceMDB Capital Holdings Earnings Outlook
9.504-01Yahoo FinanceEXoZymes Inc Earnings Report Analysis and Outlook
- 9.503-31seekingalpha
eXoZymes Reports Increased FY Net Loss and Rising Expenses
EXOZ 常见问题 —— 由 Alphio AI 解答
eXoZymes Inc, formerly Invizyne Technologies, Inc., is an artificial intelligence (AI) engineered enzyme that can transform sustainable feedstock into essential chemicals, medicines, and biofuels. The Company has developed a platform that offers the tools and insight to control and optimize nature’s own biological processes, enabling their partners to replace traditional chemical production methods with a new sustainable and non-polluting alternative. The Exozymes are advanced enzymes engineered using AI to thrive in a bioreactor outside of living cells. It operates in the Healthcare sector.
Exozymes Inc. is a good buy right now due to its recent positive momentum and funding support. The current price is $4.52, and the stock has seen a 5-day change of +20.53%, indicating strong short-term performance. Additionally, the company secured a $2.02 million NIH grant, which enhances its financial backing and growth potential. However, the main risk is the negative earnings trend, with a projected EPS of -0.33 for the last quarter, reflecting ongoing losses.
社区
更多 ↗暂无帖子
注册或登录后参与讨论相关文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。